Skip to main content
Premium Trial:

Request an Annual Quote

Benitec, Children's Cancer Institute Australia to Co-Develop Lung Cancer Rx

Premium

Benitec announced this week that it has formed a collaboration with the Children's Cancer Institute Australia for Medical Research to develop an RNAi-based therapeutic for lung cancer.

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi. A CCIA researcher and Benitec collaborator has previously demonstrated that beta III-tubulin inhibition using an expressed RNAi approach can sensitize tumors to various chemotherapeutics, it added.

Under the collaboration, Benitec and CCIA, an affiliate of the University of South Wales, will optimize expressed RNAi constructs developed by the company in vitro and in vivo, with the goal of beginning phase I testing "as soon as possible," Benitec said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.